Mostrando 10 resultados de: 45
Filtros aplicados
Subtipo de publicación
Other(45)
Publisher
American Society of Clinical Oncology(8)
Elsevier(4)
The American Association for Cancer Research(4)
American Association for Cancer Research(3)
Springer US(3)
Área temáticas
Enfermedades(43)
Farmacología y terapéutica(16)
Medicina y salud(15)
Ginecología, obstetricia, pediatría, geriatría(10)
Problemas sociales y servicios a grupos(2)
Origen
google(45)
Clinico-pathologic subtypes of breast cancer primary tumors are related to prognosis after recurrence
OtherAbstract: Background: Pathological factors, based mainly on immunohistochemistry (IHC) and histological differPalabras claves:Autores:Alejandra PérezFuentes:googleAssessment of Sacituzumab Govitecan vs Treatment of Physician’s Choice Cohort by Agent in the Phase 3 ASCENT Study of Patients With Metastatic Triple‑Negative Breast Cancer
OtherAbstract: Background • Metastatic triple‑negative breast cancer (mTNBC) is a heterogenous disease with few trePalabras claves:Autores:Alejandra PérezFuentes:googleAssessment of genetic alterations using next-generation sequencing in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from …
OtherAbstract: The BOLERO-2 phase III trial compared the combination of everolimus and exemestane to placebo and exPalabras claves:Autores:Alejandra PérezFuentes:google1481P Expression of ERBB2 and PD1 mRNA in advanced gastric cancer
OtherAbstract: Background Quantitative measurements of ERBB2 and PD1 mRNA in gastric cancer (GC) could better reflePalabras claves:Autores:Alejandra PérezFuentes:googleA multi-center phase II study of three doses of TAS-108 in postmenopausal women with advanced breast carcinoma following first or second line endocrine therapy.
OtherAbstract: Abstract #2131 Introduction: TAS-108 is an oral steroidal anti-estrogen agent that selectively inhibPalabras claves:Autores:Alejandra PérezFuentes:googleA phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer
OtherAbstract: The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of BZL101 (FDPalabras claves:Autores:Alejandra PérezFuentes:googleA phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer.
OtherAbstract:Palabras claves:Autores:Alejandra PérezFuentes:googleA phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer
OtherAbstract: This multicenter phase II trial evaluated the tolerability and efficacy of neoadjuvant chemotherapyPalabras claves:Autores:Alejandra PérezFuentes:googleCorrelation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
OtherAbstract: LBA509 Background: Everolimus (EVE) plus exemestane (EXE) more than doubled progression-free survivaPalabras claves:Autores:Alejandra PérezFuentes:googleCorrelative analysis of genetic alterations and everolimus benefit in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer …
OtherAbstract: Purpose To explore the genetic landscape of tumors from patients enrolled on the BOLERO-2 trial to iPalabras claves:Autores:Alejandra PérezFuentes:google